MD
MDBH
MDB Capital Holdings, LLC
$2.86
-9.49%
$15.6M
No data for this timeframe.
Vol
Market Cap$15.6M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$126.3K
Inst. Activity1 buys / 0 sells
Press Releases2
Recent Activity
May 1, 2026
Insider
MARLETT CHRISTOPHER A was granted 100,000 shares
Co-Founder
Apr 20, 2026
Insider
Torpey Daniel Thomas was granted 10,000 shares
Director @ $3.90 ($39.0K)
Apr 20, 2026
Insider
Torpey Daniel Thomas acquired via exercise 10,000 shares
Director
Inst.
UBS Group AG — ADD
62,593 shares ($385.5K)
Inst.
UBS Group AG — ADD
41,534 shares ($261.7K)
Jun 4, 2026
other
New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity
<p align="center">• Analysis of 20 muscle-preservation programs highlights a rapidly emerging catego
Mar 23, 2026
Press
MDB Capital Holdings, LLC (MDBH) announced plans to host a webinar on March 31, 2026, to discuss its Q4 and full-year 20
Impact 3/10
Mar 11, 2026
Press
PatentVest, a division of MDBH, completed a strategic IP engagement with biotech firm Porosome Therapeutics, providing a
Impact 4/10
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Beacon Pointe Advisors, LLC | $89.4K | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $36.9K | — |
| MORGAN STANLEY | $3.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | MARLETT CHRISTOPHER | A | $0.00 |
| Apr 20, 2026 | Torpey Daniel | A | $39.0K |
| Apr 20, 2026 | Torpey Daniel | M | $0.00 |
| Apr 20, 2026 | Magennis Sean | M | $0.00 |
| Apr 20, 2026 | James Jeremy | M | $0.00 |
3 institutional holders with $126.3K total value (42,398 shares) as of 2026-Q1. Top holders: Beacon, SUSQUEHANNA, MORGAN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Beacon Pointe Advisors, LLC | 30,000 | $89.4K | 70.8% | — |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12,397 | $36.9K | 29.2% | — |
| 3 | MORGAN STANLEY | 1 | $3.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | ADD | 41,534 | 62,593 | +50.7% | $385.5K | 2025-Q1 |
| UBS Group AG | ADD | 31,771 | 41,534 | +30.7% | $261.7K | 2024-Q4 |
5 unique insiders with 16 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | MARLETT CHRISTOPHER A | Co-Founder | AWARD | 100,000 | — | — |
| Apr 20, 2026 | Torpey Daniel Thomas | Director | AWARD | 10,000 | $3.90 | $39.0K |
| Apr 20, 2026 | Torpey Daniel Thomas | Director | EXERCISE | 10,000 | — | — |
| Apr 20, 2026 | Magennis Sean James | Director | EXERCISE | 10,000 | — | — |
| Apr 20, 2026 | James Jeremy William | CFO | EXERCISE | 10,000 | — | — |
| Feb 9, 2026 | Magennis Sean James | Director | AWARD | 10,000 | $3.90 | $39.0K |
| Feb 9, 2026 | James Jeremy William | CFO | AWARD | 10,000 | $3.90 | $39.0K |
| Feb 9, 2026 | Magennis Sean James | Director | AWARD | 10,000 | $3.20 | $32.0K |
| Feb 9, 2026 | Magennis Sean James | Director | EXERCISE | 10,000 | — | — |
| Feb 9, 2026 | Torpey Daniel Thomas | Director | AWARD | 10,000 | $3.20 | $32.0K |
| Feb 9, 2026 | Torpey Daniel Thomas | Director | EXERCISE | 10,000 | — | — |
| Feb 9, 2026 | James Jeremy William | CFO | AWARD | 10,000 | $3.20 | $32.0K |
| Feb 9, 2026 | James Jeremy William | CFO | EXERCISE | 10,000 | — | — |
| Feb 1, 2026 | Terry Jeb Barton Sr. | Director | AWARD | 100,000 | — | — |
| Aug 14, 2025 | Torpey Daniel Thomas | Director | EXERCISE | 20,000 | — | — |
| Jun 17, 2024 | Torpey Daniel Thomas | Director | AWARD | 100,000 | — | — |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
New PatentVest Pulse Report Maps the Emerging Muscle-Preservation Category Expanding the GLP-1 Opportunity
<p align="center">• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment
Jun 3, 2026
other
MDB Capital to Present at Planet MicroCap Las Vegas 2026 Along with Subsidiary PatentVest and Portfolio Company Buda Juice
<p>Addison, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC (NASDAQ: MDBH) today announced that its CEO & Co-Founder, <strong
May 27, 2026
earnings_calendar
MDBH Q1 2026 Earnings Scheduled — 2026-05-27
May 8, 2026
other
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
<p align="center">· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and em
Apr 29, 2026
other
Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
<p>Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest <i>PatentVest Pulse</i>:<b> “The Last 20%: Retatrutide, the G
Mar 31, 2026
routine
MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter
Management to Host Conference Call Today at 4:30 p.m. ET <pre>Management to Host Conference Call Today at 4:30 p.m. ET</pre>
Mar 31, 2026
other
PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment
<p>Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest <i>PatentVest Pulse</i> report, <i>“<u>The Amylin Renaissance
Mar 31, 2026
earnings_calendar
MDBH Q4 2025 Earnings Scheduled — 2026-03-31
Mar 30, 2026
other
PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork
<p>Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced a new addition to its <b>IP Legal Insights section</b> on the company w
Mar 23, 2026
earnings
MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time
<p>Addison, TX, March 23, 2026 (GLOBE NEWSWIRE) -- <b>MDB Capital Holdings, LLC, (NASDAQ: MDBH) </b>(“MDB”), a public venture platform focused on la
Mar 11, 2026
contract
PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics
<p>Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) -- PatentVest announced the completion of a strategic intellectual property engagement with Porosome